If you are looking for some new additions to your portfolio in May, then the ASX 200 stocks listed below could be worth a closer look.
That's because they have been named on Bell Potter's Australian Equities Panel for the month. The broker notes that these are the shares that it believes "offer attractive risk-adjusted returns over the long term."
It also highlights that they are "quality companies with proven track records, strong management teams and competitive advantages."
We have already covered two stocks on the list here. Let's now take a look at two more of the broker's top picks for the month. They are as follows:
Image source: Getty Images
Goodman Group (ASX: GMG)
The first ASX 200 stock that could be a buy according to Bell Potter is Goodman Group.
It is a specialist global industrial property and digital infrastructure group that owns, develops, and manages high-quality, sustainable properties that are close to consumers and provide essential infrastructure for the digital economy.
Bell Potter believes that a recent pullback in its share price has created a buying opportunity for investors. It explains:
GMG presents an attractive opportunity, particularly following its recent pullback after the capital raise. The company is well-leveraged to data centres, a high growth sector that is driving a strong future development pipeline at higher margins. As a founder-led business, GMG benefits from experienced leadership with a proven track record of robust EPS growth. Trading at ~23x forward earnings with double-digit earnings growth projected over the next few years, we believe the current valuation offers good long-term value for investors.
Telix Pharmaceuticals Ltd (ASX: TLX)
Another ASX 200 stock that makes the list this month is Telix Pharmaceuticals. It is a pharmaceutical company that specialises in the development and commercialisation of radiopharmaceuticals.
Bell Potter believes that Telix's shares are attractively priced based on its strong earnings per share (EPS) growth outlook. The broker is forecasting an EPS compound annual growth rate (CAGR) of 46% over the next two financial years. It explains:
TLX is building a vertically integrated radiopharmaceutical specialist company providing research, product development, isotope production, supply chain management and distribution in order to capture most of the margin in these highly valued assets for medical imaging and therapy. The company aims to initially dominate the urology space with a range of products for imaging, therapy and surgery. Valuations are attractive, with 12MF P/E now at 41x, supported by a 2yr EPS CAGR of 46%.
